-       Report 
- April 2023
-  115 Pages 
- Global 
   From       €4227EUR$4,750USD£3,721GBP 
          -       Report 
- August 2024
-  117 Pages 
- Global 
   From       €3515EUR$3,950USD£3,094GBP 
          -       Report 
- October 2024
-  70 Pages 
- North America 
   From       €845EUR$950USD£744GBP 
          -       Report 
- October 2024
-  70 Pages 
- Asia Pacific 
   From       €845EUR$950USD£744GBP 
          -       Report 
- October 2024
-  70 Pages 
- Latin America 
   From       €845EUR$950USD£744GBP 
           -       Report 
- October 2024
-  70 Pages 
- Europe 
   From       €845EUR$950USD£744GBP 
          -       Report 
- October 2024
-  70 Pages 
- China 
   From       €845EUR$950USD£744GBP 
          -       Report 
- October 2024
-  70 Pages 
- France 
   From       €845EUR$950USD£744GBP 
          -       Report 
- October 2024
-  70 Pages 
- Germany 
   From       €845EUR$950USD£744GBP 
          -       Report 
- October 2024
-  70 Pages 
- India 
   From       €845EUR$950USD£744GBP 
          -       Report 
- October 2024
-  70 Pages 
- United Kingdom 
   From       €845EUR$950USD£744GBP 
          -       Report 
- October 2024
-  70 Pages 
- United States 
   From       €845EUR$950USD£744GBP 
          -       Report 
- September 2024
-  117 Pages 
- Global 
   From       €4004EUR$4,500USD£3,525GBP 
          -       Report 
- December 2022
- Global 
        €4227EUR$4,750USD£3,721GBP 
          -       Report 
- March 2024
-  101 Pages 
- Global 
   From       €3500EUR$4,213USD£3,189GBP 
          -       Report 
- January 2025
-  132 Pages 
- Global 
   From       €845EUR$950USD£744GBP 
          -       Report 
- October 2024
-  70 Pages 
- Global 
   From       €845EUR$950USD£744GBP 
          -       Report 
- October 2024
-  70 Pages 
- Japan 
   From       €845EUR$950USD£744GBP 
         
      The Tumor Profiling market within the Diagnostics industry is a rapidly growing sector. It involves the use of advanced technologies such as next-generation sequencing (NGS) and polymerase chain reaction (PCR) to analyze the genetic makeup of tumors. This helps to identify the specific mutations that are driving the tumor's growth, allowing for more targeted treatments. Tumor profiling can also be used to monitor the effectiveness of treatments and to detect recurrence of the tumor.
The market is    driven by the increasing prevalence of cancer, the growing demand for personalized medicine, and the development of new technologies. Additionally, the increasing availability of genomic data and the development of artificial intelligence (AI) and machine learning (ML) are expected to further drive the market.
Some of the major companies in the Tumor Profiling market include Illumina, Thermo Fisher Scientific, Agilent Technologies, QIAGEN, and Roche. Show Less   Read more